News
Focus on the early discovery and clinical development of bispecific antibody and ADC.
Late-Breaking Preclinical Results of ALK201 Presenting at 2025 AACR Annual Meeting
Release Time：2025-03-31 17:49:49 Article Source：AllinkBio
Shanghai, China - March 31, 2025, Allink Biotherapeutics, a clinical-stage biotech company dedicated to developing next-generation bispecific antibodies and antibody-drug conjugates (ADCs), today announced that it will present the latest preclinical findings of its First-in-Class FGFR2b-targeting ADC, ALK201, at the 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago, USA. The poster will be showcased during the Late-Breaking Research: Experimental and Molecular Therapeutics 2 session.
Key Presentation Details
Abstract Title: ALK201, a First-in-Class FGFR2b-Targeting Antibody-Drug Conjugate for Patients with FGFR2b+ Gastric Cancer and Other Solid Tumors
Session Category: Late-Breaking Research
Abstract Number: LB227
Poster Section: 54, Board #1
Date/Time: April 28, 2025, 2:00 PM – 5:00 PM (Local Time)
About ALK201
ALK201 is a novel ADC designed to selectively target FGFR2b, a clinically validated oncogenic driver associated with poor prognosis in gastric, breast, and other solid tumors. Preclinical studies have demonstrated its potent anti-tumor activity and favorable therapeutic window, attributed to its proprietary hydrophilic linker and optimized payload. The drug is currently undergoing an international multicenter Phase I clinical trial to evaluate safety, tolerability, and preliminary efficacy in patients with advanced solid tumors.
About AllinkBio
Founded in 2023, AllinkBio is a clinical-stage biotechnology company leveraging its innovative proprietary platforms in bispecific antibodies and ADCs to develop a diverse pipeline of First-in-Class (FIC) and Best-in-Class (BIC) therapeutics. AllinkBio aims to develop treatment paradigm shifting new drugs for patients in the oncology and immunology disease areas and address critical unmet medical needs globally.
For Media Inquiries:
PR@Allinkbio.com
Key Presentation Details
Abstract Title: ALK201, a First-in-Class FGFR2b-Targeting Antibody-Drug Conjugate for Patients with FGFR2b+ Gastric Cancer and Other Solid Tumors
Session Category: Late-Breaking Research
Abstract Number: LB227
Poster Section: 54, Board #1
Date/Time: April 28, 2025, 2:00 PM – 5:00 PM (Local Time)
About ALK201
ALK201 is a novel ADC designed to selectively target FGFR2b, a clinically validated oncogenic driver associated with poor prognosis in gastric, breast, and other solid tumors. Preclinical studies have demonstrated its potent anti-tumor activity and favorable therapeutic window, attributed to its proprietary hydrophilic linker and optimized payload. The drug is currently undergoing an international multicenter Phase I clinical trial to evaluate safety, tolerability, and preliminary efficacy in patients with advanced solid tumors.
About AllinkBio
Founded in 2023, AllinkBio is a clinical-stage biotechnology company leveraging its innovative proprietary platforms in bispecific antibodies and ADCs to develop a diverse pipeline of First-in-Class (FIC) and Best-in-Class (BIC) therapeutics. AllinkBio aims to develop treatment paradigm shifting new drugs for patients in the oncology and immunology disease areas and address critical unmet medical needs globally.
For Media Inquiries:
PR@Allinkbio.com
